New agreement covers 1.25m additional doses, bringing total potential U.S. supply to >1.5m doses, Regeneron says.
- Agreement value as much as $2.625b
- Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate Covid-19 in order to reduce the risk of progression to severe Covid-19 and/or hospitalization
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2021 Bloomberg L.P. All rights reserved. Used...